FOSTER CITY, Calif.-Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has announced new compensation terms involving equity awards to 16 newly hired employees. The company has granted stock options for a total of 744,000 shares of common stock, alongside restricted stock units (RSUs) representing 372,000 shares. Granted on June 17, 2025, the stock options come with an exercise price of $1.45 per share, matching the closing price on the grant date. These options have a ten-year term, with vesting over four years. Similarly, the RSUs will vest annually over four years. These awards were sanctioned by Geron's Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4) and fall under the company's 2018 Inducement Award Plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.